Dr Reddys Laboratories to launch Lenalidomide Capsules in U.S. market

8 Sep 2022 , 09:21 AM

Dr Reddys Laboratories announced the introduction of Lenalidomide Capsules in the United States, a therapeutic comparable generic version of REVLIMID (lenalidomide) Capsules approved by the United States Food and Drug Administration (USFDA).

Dr Reddys is eligible for first-to-market, 180-day generic medication exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths with this volume-limited launch.

In order to satisfy all remaining claims in its case, Celgene agreed to provide Dr Reddys a license to distribute volume-limited amounts of generic lenalidomide capsules in the United States.

The agreed-upon percentages are kept private. As part of the settlement, Dr Reddys is also granted permission to sell generic lenalidomide capsules in the United States without regard to volume commencing January 31, 2026.

Dr Reddys Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg in 28-count bottles, as well as 15 mg, 20 mg, and 25 mg in 21-count bottles.

At around 9.24 AM, Dr Reddys Laboratories was trading at Rs4,281 apiece, up by 0.7% from its previous closing of Rs4,251.25 on the BSE. The scrip opened at Rs4,290.

For feedback and suggestions, write to us at [e-mail]